Search results
AbbVie Is 'Firing On All Cylinders,' But Its Stock Doesn't Show That
Investor's Business Daily· 22 hours ago"This is despite the significant increase in U.S. biosimilar market share in April," Leerink...
AbbVie tries to reassure investors on Humira biosimilar threat
BioPharma Dive via Yahoo Finance· 1 day agoAlthough that has meant Humira’s market share dropped from 96% to 81% over two weeks, Stewart said...
AbbVie (ABBV) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 23 hours agoTotal net revenues were $12.3 billion approximately $400 million ahead of our expectations. This overachievement was driven by our ex-Humira growth...
Analyst Report: AbbVie Inc.
Morningstar Research via Yahoo Finance· 1 day agoAbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off ...
AbbVie Lifts 2024 Forecast as Newer Drugs Replace Humira Losses
Bloomberg· 1 day agoAbbVie Inc. lifted its full-year profit guidance as newer anti-inflammatory treatments like Rinvoq...
Drugmaker AbbVie expects Humira volume erosion to worsen By Reuters
Investing.com· 1 day agoIts shares were down 2% in morning trade on Friday, after the company forecast U.S. Humira sales...
AbbVie (ABBV) Reports Q1 Earnings: What Key Metrics Have to Say
Zacks via Yahoo Finance· 1 day agoWhile the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed...
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 5 days agoAbbVie’s top line is being driven by sales of new immunology drugs, Skyrizi and Rinvoq. The Zacks...
AbbVie's newer drugs are offsetting losses of the world's once best-selling medication
Quartz· 1 day agoSales of the pharma giant's newer drugs are offsetting its Humira losses.
Q1 2024 AbbVie Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 13 hours agoTotal net revenues were $12.3 billion, approximately $400 million ahead of our expectations. This overachievement was driven by our ex-Humira growth platform, which delivered revenue growth ...